SAN MARINO, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Viral Genetics, a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, has completed its second major debt conversion in two months resulting in the issuance of approximately 36 million additional shares of common stock in exchange for approximately $1.2 million of principal and interest.
